SEARCH:   Advanced

Blood, 12 November 2009, Vol. 114, No. 20, pp. 4369-4372. Prepublished online as a Blood First Edition Paper on September 15, 2009; DOI 10.1182/blood-2009-05-221689. This Article Full Text Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2009-05-221689v1 114/20/4369    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Google Scholar Articles by Paiva, B. Articles by San-Miguel, J. F. PubMed PubMed Citation Articles by Paiva, B. Articles by San-Miguel, J. F. Related Collections Free Research Articles Lymphoid Neoplasia Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Brief report The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients Bruno Paiva1,*, Maria-Belén Vidriales1,2,*, Gema Mateo1,2, Jose J. Pérez1, Maria Angeles Montalbán3, Anna Sureda4, Laura Montejano3, Norma C. Gutiérrez1,2, Alfonso García de Coca5, Natalia de las Heras6, Maria Victoria Mateos1,2, Maria Consuelo López-Berges1, Raimundo García-Boyero7, Josefina Galende8, Jose Hernández9, Luis Palomera10, Dolores Carrera11, Rafael Martínez12, Javier de la Rubia13, Alejandro Martín14, Yolanda González15, Joan Bladé16, Juan José Lahuerta3, Alberto Orfao2,17, Jesús F. San-Miguel1,2, and on behalf of the GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Groups 1 Hospital Universitario de Salamanca, Salamanca; 2 Centro de Investigación del Cáncer, Salamanca; 3 Hospital 12 de Octubre, Madrid; 4 Hospital Santa Creu I Sant Pau, Barcelona; 5 Hospital Clínico Universitario de Valladolid, Valladolid; 6 Complejo Hospitalario de León, León; 7 Hospital General de Castellón, Castellón; 8 Hospital del Bierzo, Ponferrada; 9 Hospital General de Segovia, Segovia; 10 Hospital Lozano Blesa, Zaragoza; 11 Hospital Central de Asturias, Oviedo; 12 Clínico San Carlos, Madrid; 13 Hospital La Fe, Valencia; 14 Hospital Virgen de la Concha, Zamora; 15 Hospital Dr. Josep Trueta, Gerona; 16 Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer Barcelona, Barcelona; and 17 Servicio General de Citometría, Universidad de Salamanca, Salamanca, Spain Multiparameter flow cytometry immunophenotyping allows discrimination between normal (N-) and myelomatous (MM-) plasma cells (PCs) within the bone marrow plasma cell compartment (BMPCs). Here we report on the prognostic relevance of detecting more than 5% residual normal plasma cells from all bone marrow plasma cells (N-PCs/BMPCs) by multiparameter flow cytometry in a series of 594 newly diagnosed symptomatic MM patients, uniformly treated according to the Grupo Español de MM 2000 (GEM2000) protocol. Our results show that symptomatic MM patients with more than 5% N-PCs/BMPCs (n = 80 of 594; 14%) have a favorable baseline clinical prospect, together with a significantly lower frequency of high-risk cytogenetic abnormalities and higher response rates. Moreover, this group of patients had a significantly longer progression-free survival (median, 54 vs 42 months, P = .001) and overall survival (median, not reached vs 89 months, P = .04) than patients with less than or equal to 5% N-PCs/BMPCs. Our findings support the clinical value of detecting residual normal PCs in MM patients at diagnosis because this reveals a good prognostic category that could benefit from specific therapeutic approaches. This trial was registered at www.clinicaltrials.gov as NCT00560053 [ClinicalTrials.gov] . CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020